Analysis: FDA's drug-safety memo comes without context

10/20/2008 | RPM Report (free registration), The

The FDA's first quarterly Web posting on potential drug-safety problems, designed to increase transparency with consumers, lacks context and leaves investors and drug sponsors trying to understand its implications, according to this RPM Report analysis. However, the agency's authorities for risk evaluation and mitigation strategies could make the system more predictable and manageable.

View Full Article in:

RPM Report (free registration), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Financial Officer
B. E. Smith
Miramar, FL
Claims Director
Springfield, OR
Attest Health Care Advisors
Nationwide, SL_Nationwide
Biotechnology/Pharmaceutical Patent Attorney
Coats and Bennett PLLC
Cary, NC
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA